On October 27, 2020 I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, reported that the Company will present the latest preclinical data from its C5aR program, TJ210 at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 35th Anniversary Annual Meeting & Pre-Conference Programs (SITC 2020), taking place online November 9 – 14, 2020 (Press release, I-Mab Biopharma, OCT 27, 2020, View Source [SID1234569165]). The preclinical data will provide a rationale for the use of TJ210 as a monotherapy or in combination with immune checkpoint inhibitors such as anti PD-1 therapies as anti-tumor agent.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Complement component fragment 5a receptor (C5aR1, CD88) is a G-protein coupled receptor (GPCR) and is being investigated as a potential new drug target in the field of immuno-oncology. C5a is produced in the tumoral microenvironment which acts as a chemoattractant to recruit through one of its receptors namely C5aR1 pro-tumor cells such as myeloid derived suppressive cells (MDSCs), neutrophils and M2 macrophages to the tumor site to suppress the human immune system attacking on the cancer and accelerate tumor progression.
TJ210 is an anti-C5aR monoclonal antibody in-licensed from MorphoSys, designed to bind to a unique epitope on C5aR1, thereby aimed to block the recruitment of pro-tumor cells into the tumor microenvironment.
Details of the oral presentation are as follows:
Title
TJ210 (MOR210), A Differentiated Anti-C5aR Antibody for Anti-Cancer Therapy
Abstract #
607
Presenting Author
Jane Meng, PhD, I-Mab Biopharma
Presentation Time
11:30 am – 11:45 am (EST), Thursday, November 12
Visit SITC (Free SITC Whitepaper) website for more abstract information.
About TJ210/MOR210
TJ210/MOR210 is a novel human antibody directed against C5aR derived from MorphoSys’s HuCAL Platinum technology. C5aR, the receptor of the complement factor C5a, is investigated as a potential new drug target in the field of immuno-oncology and autoimmune diseases. Tumors have been shown to produce high amounts of C5a, which, by recruiting and activating myeloid-derived suppressor cells (MDSCs), M2 macrophages and neutrophils, is assumed to contribute to an immune-suppressive pro-tumorigenic microenvironment. TJ210/MOR210 is intended to block the interaction between C5a and its receptor, thereby potentially neutralizing the immune suppressive function and enabling immune cells to attack the tumor.
HuCAL and HuCAL Platinum are registered trademarks of MorphoSys AG.